Back to Search
Start Over
The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer
- Source :
- Cancer Management and Research. 12:51-57
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- Gastric cancer is the sixth most common cancer and is known to be the fifth-leading cause of cancer-related deaths globally in 2018. Systemic therapy remains the only curative option in advanced gastric carcinoma with the primary goal of improving the Health-related Quality of Life (HRQoL) (including palliation of symptoms such as dysphagia) and prolonging overall survival. Recently, ramucirumab is approved by the United States Food and Drug Administration (US-FDA) as a second-line agent either as monotherapy or in combination with paclitaxel in advanced or metastatic gastric and gastro-esophageal junction adenocarcinoma patients who have progressed on prior treatment with fluoropyrimidine or platinum containing chemotherapy. HRQoL is a subjective term that typically constitutes four components - psychological, social, occupational and physical well being. This has been evaluated as secondary endpoint in the pivotal Phase III trials with ramucirumab. HRQoL measurement can potentially provide additional information for clinical decision making beyond that of traditional medical outcomes. The present work is primarily focused on discussing HRQoL in gastric cancer patients and the impact of ramucirumab on the HRQoL in the patients with advanced gastric cancer. We also summarized the studies that evaluated the benefits of systemic therapies on HRQoL in advanced gastric cancer.
- Subjects :
- 0301 basic medicine
Oncology
Chemotherapy
medicine.medical_specialty
business.industry
medicine.medical_treatment
Cancer
medicine.disease
Dysphagia
Systemic therapy
Ramucirumab
03 medical and health sciences
chemistry.chemical_compound
030104 developmental biology
0302 clinical medicine
Paclitaxel
chemistry
Quality of life
030220 oncology & carcinogenesis
Internal medicine
medicine
Adenocarcinoma
medicine.symptom
business
Subjects
Details
- ISSN :
- 11791322
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Cancer Management and Research
- Accession number :
- edsair.doi...........a44b3194ba7e6f4ed92bf845873dcf9d